Intravitreal fluocinolone acetonide implant for the treatment of persistent post-surgical cystoid macular edema in vitrectomized eyes
Autor: | Alfredo Adán, Manuel J. Navarro-Angulo, Aina Moll-Udina, Á. Olate-Pérez, Lucia Miguel-Escuder, Anna Sala-Puigdoners, Marc Figueras-Roca, Laura Pelegrín |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Visual acuity genetic structures business.industry medicine.medical_treatment Vitrectomy General Medicine Cataract surgery medicine.disease eye diseases Posterior segment of eyeball Ophthalmology Fluocinolone acetonide medicine sense organs medicine.symptom business Macular edema Uveitis Dexamethasone medicine.drug |
Zdroj: | European journal of ophthalmology. |
ISSN: | 1724-6016 |
Popis: | Cystoid macular edema (CME) is the most common cause of decreased visual acuity after both vitrectomy and cataract surgery. Various strategies have been used for its treatment, such as intravitreal corticosteroids. The intravitreal fluocinolone acetonide implant (Iluvien®) is approved for the treatment of persisting diabetic macular edema and for the prevention of recurrence of non-infectious uveitis affecting the posterior segment. There are very few reports about its off-label use for post-surgical CME. We present four clinical cases of post-surgical CME (three following vitrectomy and one following cataract surgery in a vitrectomized eye 2 years ago). All of them had been previously treated with an average of four injections of intravitreal dexamethasone implant (Ozurdex®), with repeated recurrence of CME. After treatment with Iluvien, three cases showed improvement of both visual acuity and macular anatomy, with resolution of the macular edema. One patient required additional treatment with Ozurdex during follow-up, further improving CME. Two of the cases required topical pressure lowering treatment, and none required filtering surgery. Iluvien could be an effective therapeutic option for persistent non-diabetic macular edema after vitrectomy or cataract surgery refractory to other intravitreal therapies, with the benefit of being able to provide longer recurrence-free periods. |
Databáze: | OpenAIRE |
Externí odkaz: |